Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ADMA

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.

Investors Business Daily

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA stock rocketed Friday after the biotech company inked a deal with KPMG as its new independent registered public accounting firm.

Investors Business Daily

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns

ADMA stock plummeted Thursday after the company's auditor unexpectedly resigned. But ADMA Biologics kept its guidance for this year and next.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

Investors Business Daily

Why ADMA Biologics Shares Are Rising Today

ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.

Looking Into ADMA Biologics's Return On Capital Employed

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

Recap: ADMA Biologics Q1 Earnings

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Outlook For ADMA Biologics

Earnings Outlook For ADMA Biologics

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.

ADMA Biologics's Return On Capital Employed Overview

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

ADMA Biologics's Earnings Outlook

ADMA Biologics's Earnings Outlook

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09.

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

ADMA Biologics Inc (NASDAQ: ADMA) expects

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

Organisations

SP Global Market Intelligence

Lumen Technologies

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play